BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7648838)

  • 1. Tentative criteria for determining the in vitro susceptibilities of Haemophilus influenzae, including quality control parameters, to two fluoroquinolones (grepafloxacin and PD 131628).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Jorgensen JH; Tenover F
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):175-9. PubMed ID: 7648838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tentative interpretive criteria and quality control parameters for in-vitro susceptibility testing of Neisseria gonorrhoeae to two fluoroquinolones (PD 131628 and grepafloxacin (OPC 17116)).
    Sewell DL; Barry AL; Allen SD; Fuchs PC; Murray PR; Tenover FC
    J Antimicrob Chemother; 1996 Jan; 37(1):139-43. PubMed ID: 8647755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tentative criteria for confirming the in vitro susceptibilities of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters.
    Barry AL; Fuchs PC; Allen SD; Jorgensen JH; Tenover FC; Murray PR; Hardy DJ; Baker CN
    J Clin Microbiol; 1993 Sep; 31(9):2375-80. PubMed ID: 8408559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities and postantibiotic effects of gemifloxacin compared to those of 11 other agents against Haemophilus influenzae and Moraxella catarrhalis.
    Davies TA; Kelly LM; Hoellman DB; Ednie LM; Clark CL; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2000 Mar; 44(3):633-9. PubMed ID: 10681330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpretive criteria and quality control guidelines for lomefloxacin and meropenem in susceptibility tests of Haemophilus influenzae using Haemophilus test medium.
    Pfaller MA; Jones RN; Washington JA; Koontz FP; Gerlach EH; Erwin ME
    Diagn Microbiol Infect Dis; 1992 Feb; 15(2):145-50. PubMed ID: 1315231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, E-test comparisons, and quality control guidelines for H. influenzae.
    Jones RN; Biedenbach DJ; Erwin ME; Beach ML; Pfaller MA
    J Clin Microbiol; 1999 Jun; 37(6):1999-2002. PubMed ID: 10325362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of grepafloxacin against Haemophilus influenzae and Moraxella catarrhalis.
    Maskell JP; Whiley AC; Sefton AM
    Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):293-5. PubMed ID: 9707317
    [No Abstract]   [Full Text] [Related]  

  • 8. Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.
    Barrett MS; Jones RN
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):462-5. PubMed ID: 1330563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN; Barrett MS; Biedenbach DJ
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of in vitro susceptibility testing criteria for gemifloxacin when tested against Haemophilus influenzae strains with reduced susceptibility to ciprofloxacin and ofloxacin.
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):323-6. PubMed ID: 12151195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpretive criteria and quality control parameters for testing susceptibility of Haemophilus influenzae to enoxacin, ofloxacin, and temafloxacin.
    Barry AL; Jorgensen JH; Hardy DJ; Allen SD; Baker CN; Fuchs PC; McLaughlin JC
    J Clin Microbiol; 1992 Nov; 30(11):3013-5. PubMed ID: 1333487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Ridgway GL; O'Hare MD; Felmingham D; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):259-62. PubMed ID: 2941258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
    Bale MJ; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1994 May; 19(1):65-8. PubMed ID: 7956017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
    Odenholt I; Cars T; Lowdin E
    J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.
    Barry AL; Fuchs PC; Citron DM; Allen SD; Wexler HM
    J Antimicrob Chemother; 1993 Jun; 31(6):893-900. PubMed ID: 8395494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretive criteria and quality control parameters for testing bacterial susceptibility to the fluoroquinolone PD131628.
    Barry AL; Fuchs PC; Allen SD; Tenover FC; Jorgensen JH; Reller LB
    J Clin Microbiol; 1995 Jan; 33(1):235-8. PubMed ID: 7699050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory pathogens: assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms.
    Felmingham D
    J Antimicrob Chemother; 2000 Mar; 45():1-8. PubMed ID: 10719006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of quinolones against S. pneumoniae, H. influenzae and M. catarrhalis in Saudi Arabia.
    Balkhy HH; Memish ZA; Shibl A; Elbashier A; Osoba A
    East Mediterr Health J; 2005; 11(1-2):36-44. PubMed ID: 16532669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of the new quinolone gemifloxacin (SB-265805) with other fluoroquinolones against respiratory tract pathogens.
    García-Garrote F; Cercenado E; Martín-Pedroviejo J; Cuevas O; Bouza E
    J Antimicrob Chemother; 2001 May; 47(5):681-4. PubMed ID: 11328784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provisional quality control parameters and interpretive criteria for testing susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to quinupristin/dalfopristin (RP59500). Antimicrobial Testing Quality Control Group.
    Fuchs P; Barry A; Brown S
    Eur J Clin Microbiol Infect Dis; 1998 Mar; 17(3):197-201. PubMed ID: 9665303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.